Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the talking.
The question I want answered is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.
Not looking for reassurance. Looking for the part I have got wrong.
FDA_TrackerJim said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
RetaRick_CA said:My insurance denied my PA related to cost and coverage.
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $299/month (eating less)
- Restaurants: SAVED $189/month (fewer meals out)
- Alcohol: SAVED $139/month (stopped drinking)
- Life insurance: Premium REDUCED by $49/month (lower BMI)
- Copays: SAVED $79/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemFDA_TrackerJim said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
Can confirm. Same sequence, different timescale. Nothing to add that would improve it.
Clinical perspective, offered as context rather than as advice.
FDA_TrackerJim said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.